CDSCO grants marketing authorisation for India’s first Dengue vaccine

 

CDSCO grants marketing authorisation for India’s first Dengue vaccine

The Central Drugs Standard Control Organisation (CDSCO) has granted marketing authorisation for India’s first dengue vaccine, the attenuated dengue vaccine (Qdenga®), to strengthen national dengue prevention efforts.

This is the first dengue vaccine approved in the country for the prevention of dengue disease. The vaccine is approved for the prevention of dengue disease in individuals 4 to 60 years of age. The vaccine has already received regulatory approval in 42 countries, including the European Union, the United Kingdom, Switzerland, Indonesia, Malaysia and Thailand.

The Ministry of Health and Family Welfare said that the approval of the country’s first dengue vaccine marks an important milestone in India’s public health response to dengue. It added that it is expected to complement the ongoing vector control, surveillance and early diagnosis.